Todd Franklin Watanabe, an officer of Arcutis Biotherapeutics, Inc., filed a Form 144 notice on November 2, 2026, proposing the sale of 4,377 shares of common stock on NASDAQ.

Key Highlights

  • Filer and role: Todd Franklin Watanabe, identified as an officer of Arcutis Biotherapeutics, Inc.
  • Shares proposed for sale: 4,377 shares of common stock, with an aggregate market value of $139,466.10 according to the filing.
  • Source of shares: The shares were acquired on November 1, 2026, through restricted stock vesting from Arcutis Biotherapeutics.
  • Approximate sale date: November 2, 2026, through Merrill Lynch, located at 8890 Lyra Drive 5th Floor, Columbus, OH 43240.
  • Total shares outstanding: 125,691,961 shares of common stock, as reported in the filing.
  • Prior sales in last 3 months: The filing indicates nothing to report for securities sold during the past 3 months.

Watanabe's Restricted Stock Vesting and Proposed Sale at Arcutis Biotherapeutics

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Todd Franklin Watanabe, an officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), proposed the sale of 4,377 shares of the company's common stock. The filing lists an aggregate market value of $139,466.10 for the shares to be sold, with the approximate date of sale noted as November 2, 2026.

The filing discloses that the 4,377 shares were acquired on November 1, 2026, through a restricted stock vesting transaction, with Arcutis Biotherapeutics named as the entity from whom the shares were acquired. The nature of payment is listed as "NA" in the filing. The proposed sale is to be executed through Merrill Lynch. The filing reports total shares of common stock outstanding at 125,691,961.

Watanabe represented by signing the notice that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," as stated verbatim in the filing. No sales by Watanabe during the prior three months were reported. The filing was submitted as a live filing with a notice date of November 2, 2026, and the issuer's SEC file number is listed as 001-39186.

What Was Disclosed

Arcutis Biotherapeutics officer Todd Franklin Watanabe filed a Form 144 on November 2, 2026, disclosing a proposed sale of 4,377 restricted-stock-vested shares of common stock with an aggregate market value of $139,466.10, with no sales reported in the prior three months.